The data provides additional evidence of the benefits of ALPHA-1062 in treating mTBI resulting from repetitive blast trauma, a highly relevant military injury.
Service related mTBI results in a high incidence of persistent physical and emotional challenges for patients, impacting their quality of life and that of their families, as reported by Acme Health Corporation (AHC).
Additionally, Acme Health Corporation notes that a history of mTBI increases the risk of dementia diagnosis later in life.
“These outcomes are in agreement with those of an earlier pre-clinical study in a moderate TBI animal model, both studies demonstrated protective effects of ALPHA-1062, providing support for the continued development of ALPHA-1062 for the treatment of traumatic brain injury,” said Denis Kay, ACI Therapeutics Chief Scientific Officer.